Kyprolis (carfilzomib) is an injectable proteasome inhibitor. It is indicated for treatment of multiple myeloma in patients who have had at least two previous therapies and have shown disease progression within 60 days of their last medication therapy. Kyprolis is marketed by Onyx Pharms and was FDA approved on July 20, 2012.

From 11/01/1997 to 08/27/2012, there have been 8 reports of a serious adverse event where KYPROLIS was identified as the primary suspect drug causing that event. During that time period, the top three adverse events reported in cases where KYPROLIS was identified as the primary suspect drug were: Hypoxia, Dyspnoea and Acute Coronary Syndrome.

06/22/2012 - Onyx Pharmaceuticals’ Kyprolis Receives Positive Vote from FDA Advisory Committee
06/19/2012 - FDA Advisory Committee To Discuss Recommending Approval For Kyprolis

Average Age: 66 Years
Gender: 57% M, 43% F
Average Duration of Treatment: 131 Days

Carfilzomib
Infusion (form) Carfilzomib 45 Mg
Infusion (form) Carfilzomib Unk
Infusion (form) Carfilzomib) 45 Mg
Show All

N/A